Imugene Azer-cel Posts 86% Response Rate in Early Cohort 3 Data [VIDEO]

Imugene's azer-cel quarterly report shows six of seven patients responding in its newest trial group, while cash fell to about $5.25 million.

By Josua Ferreira -

Key Takeaways

  • Six of seven patients in the newest azer-cel trial group responded, with three showing no detectable cancer, all after an earlier drug had stopped working.
  • The older trial group reached an 81% response rate, with 22 of 27 patients responding.
  • Cash used in running the business fell 19% to $7.49 million, but only $5.25 million was left at the end of September.
  • The company raised $11.12 million from a share sale, and the report warns that funding covers just 0.70 of a quarter.
  • Chief Executive Leslie Chong has stepped down, and Dr John Le Gall has been named Chief Medical Officer.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher